In the recent study, Radiotherapy Delivered Before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer, researchers compared various forms of treatment including radiotherapy, oral palbociclib, or a combination of both. Researchers found that radiotherapy delivered before CDK4/6 inhibitors mediated superior antineoplastic effects compared with alternative treatment schedules. See more below, and the full study here.
Xstrahl to Highlight Superficial and Orthovoltage Radiotherapy Solutions for Skin Cancer and Selective Benign Conditions at ACRO Summit 2025 in Las Vegas
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Xstrahl 200, a modern orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and selective benign conditions. Visit Xstrahl at booth 220 at the ACRO Summit 2025 – The Radiation Oncology Summit located at Planet Hollywood, Las Vegas, NV from March 12-15, 2025.
